Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice

• Published in: Journal of the American Society of Nephrology Vol. 31; no. 3; pp. 560 - 577
• Main Authors: Sugahara, Mai, Tanaka, Shinji, Tanaka, Tetsuhiro, Saito, Hisako, Ishimoto, Yu, Wakashima, Takeshi, Ueda, Masatoshi, Fukui, Kenji, Shimizu, Akira, Inagi, Reiko, Yamauchi, Toshimasa, Kadowaki, Takashi, Nangaku, Masaomi
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.03.2020
• Subjects: Animals; Basic Research; Chemokine CCL2 - drug effects; Chemokine CCL2 - metabolism; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Nephropathies - metabolism; Diabetic Nephropathies - prevention & control; Disease Models, Animal; Insulin Resistance; Metabolic Diseases - etiology; Metabolic Diseases - prevention & control; Mice; Mice, Obese; N-substituted Glycines - pharmacology; Prolyl Hydroxylases - metabolism; Prolyl-Hydroxylase Inhibitors - pharmacology; Pyridines - pharmacology; Random Allocation; Reference Values; Treatment Outcome; Triazoles - pharmacology; diabetic kidney disease; monocyte chemoattractant protein-1; adiponectin; prolyl hydroxylase domain inhibitors
• ISSN: 1046-6673; 1533-3450; 1533-3450
• DOI: 10.1681/ASN.2019060582

Prolyl hydroxylase domain (PHD) inhibitors, which stimulate erythropoietin production through the activation of hypoxia-inducible factor (HIF), are novel therapeutic agents used for treating renal anemia. Several PHD inhibitors, including enarodustat, are currently undergoing phase 2 or phase 3 clinical trials. Because HIF regulates a broad spectrum of genes, PHD inhibitors are expected to have other effects in addition to erythropoiesis, such as protection against metabolic disorders. However, whether such beneficial effects would extend to metabolic disorder-related kidney disease is largely unknown. We administered enarodustat or vehicle without enarodustat in feed to diabetic black and tan brachyury (BTBR) mice from 4 to 22 weeks of age. To elucidate molecular changes induced by enarodustat, we performed transcriptome analysis of isolated glomeruli and experiments using murine mesangial cells. Compared with BTBR mice that received only vehicle, BTBR mice treated with enarodustat displayed lower body weight, reduced blood glucose levels with improved insulin sensitivity, lower total cholesterol levels, higher adiponectin levels, and less adipose tissue, as well as a tendency for lower macrophage infiltration. Enarodustat-treated mice also exhibited reduced albuminuria and amelioration of glomerular epithelial and endothelial damage. Transcriptome analysis of isolated glomeruli revealed reduced expression of C-C motif chemokine ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP-1) in enarodustat-treated mice compared with the vehicle-only group, accompanied by reduced glomerular macrophage infiltration. experiments demonstrated that both local HIF-1 activation and restoration of adiponectin by enarodustat contributed to CCL2/MCP-1 reduction in mesangial cells. These results indicate that the PHD inhibitor enarodustat has potential renoprotective effects in addition to its potential to protect against metabolic disorders.